April 21, 2022
Amgen rolled out its lung cancer drug Lumakras (sotorasib) in Japan on April 20, making the world’s first KRAS inhibitor available for Japanese patients with oncogenic mutations that were long considered as undruggable. Lumakras obtained NHI price listing the same...read more